Pfizer's vaccine trial 'raises the bar' for other pharmaceutical companies: Jefferies' Jared Holz

Jared Holz, Jefferies, healthcare equity strategist, joins 'Closing Bell' to talk about his thoughts on Pfizer's 90 percent effective vaccine trial that's driving the markets today. He says the result pushes other pharmaceutical companies to produce effective, low-cost vaccines.
Mon, Nov 9 20204:05 PM EST